Conditions

GLP-1 and Fatty Liver Disease (MASH): Evidence and New Approvals

GLP-1 Companion · 8 min read

Metabolic-associated steatohepatitis — MASH, the liver disease formerly known as NASH — affects an estimated 16 million Americans and is now the leading cause of liver transplant waitlist additions in the United States. Until recently, there were no FDA-approved medications to treat it. That changed in August 2025, when semaglutide (Wegovy) received FDA accelerated approval for noncirrhotic MASH with significant liver fibrosis, based on compelling data from the ESSENCE trial.

Terminology Update: NAFLD, NASH, MASLD, and MASH

In 2023, the hepatology community updated the terminology for metabolic liver disease to better reflect its underlying causes and remove the stigmatizing "non-alcoholic" framing. NAFLD (non-alcoholic fatty liver disease) was renamed MASLD (metabolic dysfunction-associated steatotic liver disease). NASH (non-alcoholic steatohepatitis) — the inflammatory, fibrosis-prone form — was renamed MASH (metabolic dysfunction-associated steatohepatitis).

The new naming emphasizes the metabolic drivers: obesity, insulin resistance, type 2 diabetes, hypertension, and dyslipidemia. This framing helps explain why GLP-1 receptor agonists — which directly address these metabolic root causes — are emerging as the most promising pharmaceutical treatment for MASH.

Why GLP-1 Medications Are Directly Relevant to MASH

The two primary drivers of MASLD and MASH are obesity and insulin resistance. Insulin resistance causes the liver to increase de novo lipogenesis — the production of new fat — while also reducing fat export, leading to hepatic fat accumulation. When liver fat reaches high enough levels and triggers an inflammatory response, it progresses to MASH, which can cause fibrosis (scarring), cirrhosis, and ultimately liver failure or hepatocellular carcinoma.

GLP-1 receptor agonists address both root causes simultaneously. They reduce insulin resistance, promote significant weight loss, and have direct effects on liver cells (hepatocytes) through GLP-1 receptors expressed in the liver. This combination makes them uniquely positioned among all pharmacological options for MASH treatment.

The ESSENCE Trial: Semaglutide for MASH

The ESSENCE trial enrolled patients with biopsy-confirmed MASH and liver fibrosis (stages F1 through F3 — the trial excluded cirrhosis, which is F4). Participants were randomized to semaglutide 2.4mg weekly (the Wegovy dose) or placebo for 72 weeks. The primary endpoints were MASH resolution without worsening of fibrosis, and fibrosis improvement without worsening of MASH activity.

• MASH resolution (no steatohepatitis on repeat biopsy): 62% with semaglutide versus 34% with placebo.
• Improvement in liver fibrosis by at least one stage: 36% with semaglutide versus 22% with placebo.
• The combination endpoint (MASH resolution AND fibrosis improvement) was also significantly superior with semaglutide.
• Liver enzyme markers (ALT, AST) improved substantially in semaglutide participants.
• Based on these results, FDA granted accelerated approval to Wegovy for noncirrhotic MASH with significant fibrosis in August 2025.

Tirzepatide SYNERGY-NASH: Even More Striking Data

While semaglutide led the way to FDA approval, tirzepatide's SYNERGY-NASH trial data may ultimately prove even more impressive. The trial evaluated three doses of tirzepatide (5mg, 10mg, 15mg) versus placebo in patients with biopsy-confirmed MASH.

• At the highest tirzepatide dose (15mg), MASH resolution was achieved in 73.3% of participants versus 13.2% in the placebo group.
• That 73.3% resolution rate is among the most dramatic efficacy results ever reported in a liver disease clinical trial.
• Fibrosis improvement was also significantly superior at all tirzepatide doses versus placebo.
• An NDA (new drug application) filing with the FDA for tirzepatide in MASH is expected, potentially adding a second GLP-1 approval in this indication.

Mechanisms: How GLP-1 Medications Heal the Liver

GLP-1 receptor agonists work on MASH through several complementary mechanisms. Understanding these pathways helps explain why the clinical results are so robust compared to prior treatments that addressed only one aspect of the disease.

• Reduction of insulin resistance decreases hepatic de novo lipogenesis — the liver produces less new fat.
• Significant weight loss (typically 15–20% with tirzepatide) reduces the total hepatic fat burden directly.
• GLP-1 receptors on hepatocytes directly reduce inflammatory signaling and oxidative stress in liver cells.
• Reduced visceral fat decreases the flux of free fatty acids through the portal circulation to the liver.
• Improved glycemic control reduces glucotoxicity, which contributes to hepatic inflammation.
• Anti-inflammatory effects throughout the body (reduced CRP, IL-6, TNF-alpha) reduce the systemic inflammatory milieu that drives MASH progression.

Who Benefits Most from GLP-1 Therapy for MASH

Not every patient with fatty liver disease has the same risk profile or the same likelihood of progression. GLP-1 medications are most clearly indicated — and most likely to produce the greatest benefit — in specific patient groups.

• Patients with type 2 diabetes AND MASLD/MASH: this combination significantly accelerates fibrosis progression and cardiovascular risk.
• Patients with obesity (BMI ≥30) and elevated liver enzymes (ALT, AST above normal range).
• Patients with biopsy-confirmed MASH with fibrosis stage F1 through F3 — the population studied in ESSENCE.
• Patients with metabolic syndrome (hypertension, dyslipidemia, central obesity, impaired glucose tolerance) who also have imaging evidence of hepatic steatosis.

MASH is a silent disease. Most patients have no symptoms until fibrosis is advanced. The availability of semaglutide as an FDA-approved MASH treatment creates a new imperative: screen patients with obesity and type 2 diabetes for liver disease, and treat early while the fibrosis is still reversible.

What Tests to Monitor

Patients with known or suspected MASLD who start GLP-1 therapy should have structured laboratory and imaging monitoring to assess treatment response and guide ongoing management.

• ALT, AST, and GGT: check at baseline, then every 3–6 months during treatment. Declining liver enzymes signal improving hepatic inflammation.
• FibroScan (transient elastography) or MR elastography: non-invasive assessment of liver stiffness (fibrosis stage). Repeat every 12–24 months depending on baseline fibrosis.
• MRI-PDFF (proton density fat fraction): gold standard for quantifying liver fat percentage. Useful to confirm treatment response without biopsy.
• Fasting glucose and HbA1c: closely linked to liver disease activity; improving glycemic control often correlates with liver improvement.
• Consider hepatology referral for patients with F2–F3 fibrosis or rapidly rising liver enzymes.

Important Limitations: Cirrhosis and Advanced Disease

The FDA approval for semaglutide and the SYNERGY-NASH tirzepatide data both specifically excluded patients with cirrhosis (fibrosis stage F4). GLP-1 medications have not been adequately studied in patients with established cirrhosis, and the pharmacokinetic and safety profile in advanced liver disease is not well characterized.

The Broader Picture: A New Era for Liver Disease Treatment

For decades, MASH had no approved treatments — the standard of care was lifestyle modification alone, which few patients sustained long enough to meaningfully reverse fibrosis. The 2025 approval of semaglutide for MASH, combined with the expected tirzepatide filing, marks the beginning of a new era in hepatology. Combined with FXR agonists and other emerging agents, GLP-1 medications are likely to become the cornerstone of MASH pharmacotherapy — particularly for the large population of patients who also have obesity and type 2 diabetes.

Sources

• Newsome et al. (2021). A Placebo-Controlled Trial of Semaglutide in Nonalcoholic Steatohepatitis. NEJM.
• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.